Our vision provides a clear focus for our Strategic Directions. Our values will guide our work towards them.
Improving outcomes of people affected by cancer through research in radiation medicine.
TROG will conduct world-class research in radiation medicine that leads the global effort to better control and cure cancer, and improve outcomes for people affected by cancer.
- We will work with key stakeholders, organisations and community groups who share our aim in defeating cancer
- Improve access to world-class clinical trials
- Increase participation in clinical trials
- Ensure our research is guided by rigour, accuracy and innovative methodology
- Strive for excellence in all our endeavours
- Be a leader in radiation medicine research
- Be innovative in our research and embrace new technologies
- Provide the utmost care to trial participants, TROG members, staff and the general community
Strategic Goal | 1. Lead a high impact clinical research portfolio | 2. Cultivate collaborations and partnerships | 3. Foster stakeholder engagement and communication | 4. Build organisational capacity and sustainability |
---|---|---|---|---|
Strategic statement | Conduct high quality clinically meaningful research that responds to and is reflective of patient needs, changes in cancer treatments, new technologies, the research environment, and our membership | Proactively build strategic collaborations with Collaborative Clinical Trials Groups (CCTGs), Medical Research Institutions (MRIs), universities, government agencies and other groups in the fight against cancer | Increase community awareness, foster relationships with funding bodies/government and engage with the TROG membership | Develop systems, processes and strategies that guarantee TROG’s capacity, capability and sustainability (financial, human resources, infrastructure) |
Strategic activities | 1.1 Provide leadership in practice practice-changing research | 2.1 Build partnerships with relevant aligned organisations | 3.1 Increase brand recognition and awareness through active promotion to the community, industry, government and other research innovators | 4.1 Effective systems for TROG Central Office business processes - HR, WHS, Finance, legal, PCO, IT |
1.2 Maintain and encourage a diverse portfolio of research activity | 2.2 Collaborations with other CCTGs | 3.2 Work proactively and competitively to position TROG favourably with all stakeholders: funding bodies/ philanthropic /government/industry partners | 4.2 Continually improve processes to add value and minimise waste | |
1.3 Facilitate access to quality radiation research and clinical trials | 2.3 Establish international collaborations in strategic research areas | 3.3 Support research dissemination/implementation and promote TROG research achievements | 4.3 Implement succession planning for key critical roles (clinical and non-clinical) | |
1.4 Maintain a stream of new clinical research concepts and clinical trials | 2.4 Engage with industry partners and private sector care providers | 3.4 Foster and maintain active communications to the membership and community by TROG leadership group | 4.4 Support professional development and capacity building | |
1.5 Maximise the value of research data | 2.5 Engage with the industry to develop biologically driven and technology technology-driven trials | 3.5 Active and responsive multidisciplinary membership | 4.5 Maintain diversity of funding sources | |
1.6 Provision of superior quality clinical research support services | 2.6 Foster meaningful consumer engagement | 3.6 Nurture the future generation of TROG researchers | 4.6 Develop new business models and commercial ventures |
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292